ATXS - NASDAQ
Astria Therapeutics, Inc.
$12.58
+0.0000%Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
At a Glance
Live SnapshotAstria Therapeutics, Inc. Profit Bridge
Profitability Analysis
Astria Therapeutics, Inc. Income Statement
ATXS • NASDAQ
| Astria Therapeutics, Inc. Income Statement | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 500K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | |||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (26K) | (119K) | (0.0) | (395K) | (202K) | (0.0) | (0.0) | (0.0) | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -26K | -119K | 500K | -395K | -202K | 0.0 | 0.0 | 0.0 | |
OPERATING INCOME | |||||||||||||
(111.6M) | (83M) | (53.5M) | (195M) | (37.4M) | (27.1M) | (26.4M) | (27.6M) | (35.6M) | (31.7M) | (21.7M) | (18.1M) | (15.7K) | |
(35.3M) | (25.7M) | (19.7M) | (14.8M) | (11.8M) | (8.8M) | (9.3M) | (8.9M) | (10.1M) | (8.6M) | (6M) | (4.1M) | (4K) | |
(77.1M) | (57.3M) | (34.3M) | (15.6M) | (25.6M) | (18.3M) | (17M) | (18.7M) | (25.5M) | (23M) | (15.7M) | (14M) | (12.4K) | |
-111.6M | -83M | -53.5M | -195M | -37.4M | -27.1M | -26.4M | -27.1M | -35.6M | -31.7M | -21.7M | -18.1M | -15.7K | |
PRE-TAX INCOME | |||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (100K) | (462K) | (837K) | (978K) | (206K) | (0.0) | (0.0) | |
17.4M | 10.2M | 1.7M | 122K | 236K | 0.0 | 325K | -302K | -595K | 0.0 | 0.0 | 0.0 | 0.0 | |
-801K | (0.0) | -487K | (164.6M) | (0.0) | (0.0) | (176K) | (32K) | (93K) | (7K) | (3K) | (1K) | (0.0) | |
17.3M | 10.1M | 1.7M | 64K | 135K | 795K | 501K | -270K | -502K | -971K | -203K | 1K | 4.0 | |
-94.3M | -72.9M | -51.8M | -194.9M | -37.3M | -26.3M | -25.9M | -27.4M | -36.1M | -32.6M | -21.9M | -18.1M | -15.7K | |
NET INCOME | |||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (209K) | (0.0) | (0.0) | |
-94.3M | -72.9M | -51.8M | -194.9M | -37.3M | -26.2M | -25.9M | -27.4M | -36.1M | -32.6M | -21.9M | -18.1M | -15.7K |
SEC Filings
ATXS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | January 23, 2026 | January 23, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 21, 2026 | January 21, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 23, 2025 | December 17, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 12, 2025 | November 12, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 14, 2025 | October 14, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 12, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 06, 2025 | August 06, 2025 | 2025 | |
8-K 8-K 2025 N/A | June 12, 2025 | June 11, 2025 | 2025 | |
10-Q 10-Q 2025 Q1 Q1 | May 13, 2025 | March 31, 2025 | 2025 |
Related Guides
Continue your ATXS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.